25 results on '"Najafi Fard S"'
Search Results
2. Multi-omics approach to COVID-19: a domain-based literature review
- Author
-
Chiara Montaldo, Francesco Messina, Isabella Abbate, Manuela Antonioli, Veronica Bordoni, Alessandra Aiello, Fabiola Ciccosanti, Francesca Colavita, Chiara Farroni, Saeid Najafi Fard, Emanuela Giombini, Delia Goletti, Giulia Matusali, Gabriella Rozera, Martina Rueca, Alessandra Sacchi, Mauro Piacentini, Chiara Agrati, Gian Maria Fimia, Maria Rosaria Capobianchi, Francesco Nicola Lauria, Giuseppe Ippolito, Montaldo, C., Messina, F., Abbate, I., Antonioli, M., Bordoni, V., Aiello, A., Ciccosanti, F., Colavita, F., Farroni, C., Najafi Fard, S., Giombini, E., Goletti, D., Matusali, G., Rozera, G., Rueca, M., Sacchi, A., Piacentini, M., Agrati, C., Fimia, G. M., Capobianchi, M. R., Lauria, F. N., and Ippolito, G.
- Subjects
COVID-19 ,Conceptual domain ,Host signatures ,Omics ,Pathways ,Phenotypes ,SARS-CoV-2 ,Settore BIO/06 ,Pandemic ,General Medicine ,Review ,General Biochemistry, Genetics and Molecular Biology ,Immunity, Innate ,Phenotype ,Host signature ,Omic ,Medicine ,Humans ,Pandemics ,Pathway ,Human - Abstract
Background Omics data, driven by rapid advances in laboratory techniques, have been generated very quickly during the COVID-19 pandemic. Our aim is to use omics data to highlight the involvement of specific pathways, as well as that of cell types and organs, in the pathophysiology of COVID-19, and to highlight their links with clinical phenotypes of SARS-CoV-2 infection. Methods The analysis was based on the domain model, where for domain it is intended a conceptual repository, useful to summarize multiple biological pathways involved at different levels. The relevant domains considered in the analysis were: virus, pathways and phenotypes. An interdisciplinary expert working group was defined for each domain, to carry out an independent literature scoping review. Results The analysis revealed that dysregulated pathways of innate immune responses, (i.e., complement activation, inflammatory responses, neutrophil activation and degranulation, platelet degranulation) can affect COVID-19 progression and outcomes. These results are consistent with several clinical studies. Conclusions Multi-omics approach may help to further investigate unknown aspects of the disease. However, the disease mechanisms are too complex to be explained by a single molecular signature and it is necessary to consider an integrated approach to identify hallmarks of severity.
- Published
- 2021
3. A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients
- Author
-
Fabrizio Cantini, Alba Grifoni, Alessandra Vergori, Fabrizio Palmieri, Elisa Petruccioli, Gilda Cuzzi, Gina Gualano, Andrea Antinori, Linda Petrone, Delia Goletti, Pietro Vittozzi, Giuseppe Ippolito, Tonino Alonzi, Luciana Lepore, Saeid Najafi Fard, Emanuele Nicastri, Enrico Girardi, Nadia Caccamo, Concetta Castilletti, Valentina Vanini, Petrone L., Petruccioli E., Vanini V., Cuzzi G., Najafi Fard S., Alonzi T., Castilletti C., Palmieri F., Gualano G., Vittozzi P., Nicastri E., Lepore L., Antinori A., Vergori A., Caccamo N., Cantini F., Girardi E., Ippolito G., Grifoni A., and Goletti D.
- Subjects
Male ,0301 basic medicine ,medicine.medical_treatment ,Basic fibroblast growth factor ,chemistry.chemical_compound ,0302 clinical medicine ,T-cell based tests ,Medicine ,030212 general & internal medicine ,IFN-γ ,Antigens, Viral ,Macrophage inflammatory protein ,biology ,Interleukin ,General Medicine ,Middle Aged ,Whole blood ,Vascular endothelial growth factor ,Infectious Diseases ,medicine.anatomical_structure ,Spike Glycoprotein, Coronavirus ,Cytokines ,Original Article ,Female ,Platelet-derived growth factor receptor ,Adult ,Microbiology (medical) ,Specific response ,030106 microbiology ,COVID-19 Serological Testing ,Interferon-gamma ,03 medical and health sciences ,Th2 Cells ,Antigen ,Humans ,Immune response ,Aged ,SARS-CoV-2 ,business.industry ,Growth factor ,Monocyte ,COVID-19 ,Multiplex analysis ,Th1 Cells ,Serology response ,chemistry ,Immunoglobulin G ,Immunology ,biology.protein ,business - Abstract
Objectives To examine whether specific T-cell-responses to SARS-CoV-2 peptides can be detected in COVID-19 using a whole-blood experimental setting, which may be further explored as potential diagnostic tool. Methods We evaluated IFN-γ levels after stimulating whole-blood with spike and remainder-antigens peptides megapools (MP) derived from SARS-CoV-2 sequences; IL-1β, IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17A, eotaxin, basic FGF, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF, RANTES, TNF-α, VEGF were also evaluated. Results IFN-γ-response to spike and remainder-antigens MPs was significantly increased in 35 COVID-19-patients compared to 29 “NO COVID-19”-individuals (medians spike-MP: 0.26 vs 0, p=0.0002; medians remainder-antigens-MP: 0.07 vs 0.02; p=0.02). This response was detected independently of patients’ clinical parameters. IFN-γ-response to SARS-CoV-2-unrelated antigens CMV and SEB was similar in COVID-19 compared to NO-COVID-19-invididuals (median CMV: 3.46 versus 5.28, p=0.16; median SEB: 12.68 versus 15.05; p=0.1). In response to spike-MPs in COVID-19- compared to “NO COVID-19”-individuals, we found significant higher median of IL-2 (50.08 vs 0, p=0.0018), IFN-γ (90.16 vs 0, p=0.01), IL-4 (0.52 vs 0, p=0.03), IL-13 (0.84 vs 0, p=0.007) and MCP-1 (4602 vs 359.2, p=0.05). Conclusions Immune response to SARS-CoV-2 peptides in a whole-blood assay is associated to COVID-19 and it is characterized by both Th1 and Th2 profile. This experimental approach may be useful for developing new T-cell based diagnostic tests for disease and vaccine settings., Graphical abstract Image 1
- Published
- 2021
4. Evaluation of the Local and Peripheral Immune Responses in Patients with Cystic Echinococcosis.
- Author
-
Petrone L, Najafi-Fard S, Falasca L, Sbarra S, Teggi A, Nicastri E, Grillo LR, Burocchi M, Ettorre GM, Ludovisi A, Colombo D, Del Nonno F, and Goletti D
- Abstract
Background: Cystic echinococcosis (CE) cysts may persist for decades because of immune modulation mechanisms. Here, we characterize the cysts and the blood immune responses in patients with CE., Methods: We enrolled 61 patients with CE and 19 control subjects. We received tissue samples from seven patients with CE and a control subject requiring liver cystectomy. The immunohistochemistry evaluation of the immune cell subtypes and cytokines in the pericysts and surrounding liver and the antigen B (AgB)-specific response analysis of whole blood were performed., Results: In CE, the pericyst and the surrounding liver parenchyma showed aggregates of CD3
+ T lymphocytes, mainly CD4+ . B lymphocyte aggregates were present in the liver tissue. Monocytes/granulocytes were rarely observed. Th2 cytokine expression was scarce, whereas IFN-γ expression was present in the CE tissues. The control subject did not show an inflammatory infiltrate. The IL-4-specific response to AgB was increased in the patients with CE compared to the control, and this result was confirmed in a larger cohort ( p = 0.003), whereas the IFN-γ-response was similar between the two groups ( p = 0.5570)., Conclusion: In patients with CE, CD4+ lymphocytes infiltrate the pericyst and the surrounding liver tissue with a low IL-4/IL-13 expression level and a moderate IFN-γ expression level; moreover, an IL-4 parasite-specific response is detected in the periphery. These results support adventitia involvement in CE immunopathogenesis.- Published
- 2024
- Full Text
- View/download PDF
5. Alternative biomarkers of tuberculosis infection in patients with immune-mediated inflammatory diseases.
- Author
-
Petruccioli E, Petrone L, Najafi-Fard S, Navarra A, Vanini V, Cuzzi G, Cantini F, Gualano G, Palmieri F, and Goletti D
- Abstract
Introduction: IFN-γ release assays (IGRAs) are one of the referral tests for diagnosing tuberculosis infection (TBI). To improve IGRAs accuracy, several markers have been investigated. Patients with immune-mediated inflammatory diseases (IMID), taking biological drugs, have a higher risk to progress to TB-disease compared to the general population. In several guidelines, annual TBI screening is recommended for patients undergoing biological therapy. Aim of this study was to investigate, within the QuantiFERON-TB-Plus (QFT-Plus) platform, if beside IFN-γ, alternative biomarkers help to diagnose TBI-IMID patients., Methods: We enrolled 146 subjects: 46 with TB disease, 20 HD, 35 with TBI and 45 with TBI and IMID. Thirteen IMID subjects with a QFT-Plus negative result were diagnosed as TBI based on radiological evidence of TBI. We evaluated the IP-10 level in response to TB1 and TB2 peptides of QFT-Plus assay and we compared these results with the standardized assay based on IFN-γ. Multiplex immune assay was performed on plasma from TB1 and TB2 tubes and results were analyzed by a gradient boosting machine (GBM) as learning technique., Results: TBI-IMID showed a significant decreased IP-10 level in response to TB1 and TB2 stimulation compared to TBI-NO IMID ( p < 0.0001 and p = 0.0002). The TBI-IMID showed a moderate agreement between the IP-10-based assay and QFT-Plus scores. In TBI-IMID, QFT-Plus showed 70% sensitivity for TBI detection whereas the IP-10-based assay reached 61%. Tests combination increased the sensitivity for TBI diagnosis up to 77%. By a GBM, we explored alternative biomarkers for diagnosing TBI in IMID population reaching 89% sensitivity. In particular, the signature based on IL-2, IP-10, and IL-9 detection was associated with TB status (infection/disease). However, by applying the cut-off identified by ROC analysis, comparing TB and TBI with the HD group, within the IMID population, we did not improve the accuracy for TBI-diagnosis. Similarly, this signature did not improve TBI diagnosis in IMID with radiological evidence of TBI but negative QFT-Plus score., Discussion: To develop alternative strategies for TBI immune-diagnosis, future studies are needed to evaluate the memory response of TBI defined by radiological tools. These results may help in tuberculosis management of patients taking lifelong immune-suppressive drugs., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision., (Copyright © 2023 Petruccioli, Petrone, Najafi-Fard, Navarra, Vanini, Cuzzi, Cantini, Gualano, Palmieri and Goletti.)
- Published
- 2023
- Full Text
- View/download PDF
6. Initial immune response after exposure to Mycobacterium tuberculosis or to SARS-COV-2: similarities and differences.
- Author
-
Aiello A, Najafi-Fard S, and Goletti D
- Subjects
- Humans, SARS-CoV-2, Immunity, Mycobacterium tuberculosis, COVID-19, Latent Tuberculosis, Communicable Diseases
- Abstract
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb) and Coronavirus disease-2019 (COVID-19), whose etiologic agent is severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), are currently the two deadliest infectious diseases in humans, which together have caused about more than 11 million deaths worldwide in the past 3 years. TB and COVID-19 share several aspects including the droplet- and aerosol-borne transmissibility, the lungs as primary target, some symptoms, and diagnostic tools. However, these two infectious diseases differ in other aspects as their incubation period, immune cells involved, persistence and the immunopathological response. In this review, we highlight the similarities and differences between TB and COVID-19 focusing on the innate and adaptive immune response induced after the exposure to Mtb and SARS-CoV-2 and the pathological pathways linking the two infections. Moreover, we provide a brief overview of the immune response in case of TB-COVID-19 co-infection highlighting the similarities and differences of each individual infection. A comprehensive understanding of the immune response involved in TB and COVID-19 is of utmost importance for the design of effective therapeutic strategies and vaccines for both diseases., Competing Interests: Author DG has been a member of the advisory board of Biomerieux and Eli Lilly in 2020 and 2021 and is currently scientific advisor of PDB Biotec. She received fees for educational training or consultancy from Almirall, Biogen, Celgene, Diasorin, Janssen, Qiagen and Quidel. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Aiello, Najafi-Fard and Goletti.)
- Published
- 2023
- Full Text
- View/download PDF
7. Characterization of the immune impairment of patients with tuberculosis and COVID-19 coinfection.
- Author
-
Najafi-Fard S, Aiello A, Navarra A, Cuzzi G, Vanini V, Migliori GB, Gualano G, Cerva C, Grifoni A, Sette A, Vaia F, Palmieri F, and Goletti D
- Subjects
- Humans, Tumor Necrosis Factor-alpha, Macrophage Colony-Stimulating Factor, SARS-CoV-2 metabolism, Cytokines, Coinfection, COVID-19 complications, Tuberculosis, Mycobacterium tuberculosis
- Abstract
Objectives: To characterize the plasma immune profile of patients with tuberculosis (TB)-COVID-19 compared with COVID-19, TB, or healthy controls and to evaluate in vitro the specific responses to SARS-CoV-2 and Mycobacterium tuberculosis (Mtb)-antigens., Methods: We enrolled 119 subjects: 14 TB-COVID-19, 47 COVID-19, 38 TB, and 20 controls. The plasmatic levels of 27 immune factors were measured at baseline using a multiplex assay. The specific response to SARS-CoV-2 and Mtb antigens was evaluated using a home-made whole blood platform and QuantiFERON-Plus tubes, respectively., Results: We found an immune signature (tumor necrosis factor [TNF]-α, macrophage inflammatory protein-1β, and interleukin [IL]-9) associated with TB-COVID-19 coinfection compared with COVID-19 (P <0.05), and TNF-α showed the highest discriminant power. We also found another signature (TNF-α, IL-1β, IL-17A, IL-5, fibroblast growth factor-basic, and granulocyte macrophage colony-stimulating factor [GM-CSF]) in coinfected patients compared with patients with TB (P <0.05), and among them, TNF-α and granulocyte macrophage colony-stimulating factor showed a non-negligible discriminating ability. Moreover, coinfected patients showed a significantly reduced SARS-CoV-2-specific response compared with COVID-19 for several pro-inflammatory cytokines/chemokines, anti-inflammatory cytokines, and growth factors (P ≤0.05). Furthermore, coinfection negatively affected the Mtb-specific response (P ≤0.05)., Conclusion: We found immune signatures associated with TB-COVID-19 coinfection and observed a major impairment of SARS-CoV-2-specific and, to a lesser extent, the Mtb-specific immune responses. These findings further advance our knowledge of the immunopathology of TB-COVID-19 coinfection., Competing Interests: Declaration of competing interest AS is a consultant for Gritstone, Flow Pharma, Merck, Epitogenesis, Gilead, and Avalia. DG has been a member of the advisory board of Biomerieux and Eli-Lilly and received fees for educational training or consultancy by Biogen, Cellgene, Diasorin, Janssen, QIAGEN, and Quidel. The remaining authors have no competing interests to declare., (Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
8. Antigen discovery by bioinformatics analysis and peptide microarray for the diagnosis of cystic echinococcosis.
- Author
-
Batisti Biffignandi G, Vola A, Sassera D, Najafi-Fard S, Gomez Morales MA, Brunetti E, Teggi A, Goletti D, Petrone L, and Tamarozzi F
- Subjects
- Animals, Humans, Antigens, Helminth, Peptides, Enzyme-Linked Immunosorbent Assay methods, Computational Biology, Echinococcosis diagnosis, Echinococcus granulosus
- Abstract
Background: Cystic echinococcosis (CE), caused by Echinococcus granulosus sensu lato, is a neglected zoonosis. Its diagnosis relies on imaging, supported by serology, while only imaging is useful for staging and follow-up. Since diagnostic tools and expertise are not widely available, new accurate and easily implementable assays for the diagnosis and follow-up of CE are highly needed., Methodology/principal Findings: We aimed to identify new E. granulosus antigens through a bioinformatics selection applied to the parasite genome, followed by peptide microarray screening and validation in ELISA, using independent panels of sera from patients with hepatic CE and clinically relevant controls. From 950 proteins selected in silico, 2,379 peptides were evaluated by microarray for IgG reactivity and eight candidates selected for validation. Reactivity to one peptide was significantly higher in the CE group (p = 0.044), but had suboptimal diagnostic accuracy., Conclusions/significance: Here we performed bioinformatics analysis and peptide microarray for antigen discovery, useful for the diagnosis of CE. Eight candidates were selected and validated. Reactivity to one peptide associated to CE but had suboptimal diagnostic accuracy. Importantly, the database developed in this study may be used to identify other antigenic candidates for CE diagnosis and follow-up., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2023 Batisti Biffignandi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2023
- Full Text
- View/download PDF
9. Evaluation of the immunomodulatory effects of interleukin-10 on peripheral blood immune cells of COVID-19 patients: Implication for COVID-19 therapy.
- Author
-
Najafi-Fard S, Petruccioli E, Farroni C, Petrone L, Vanini V, Cuzzi G, Salmi A, Altera AMG, Navarra A, Alonzi T, Nicastri E, Palmieri F, Gualano G, Carlini V, Noonan DM, Albini A, and Goletti D
- Subjects
- Granulocyte-Macrophage Colony-Stimulating Factor, HLA-DR Antigens analysis, Humans, Interleukin-2, Interleukin-6, SARS-CoV-2, Tumor Necrosis Factor-alpha, COVID-19, Interleukin-10
- Abstract
Objective: Several therapies with immune-modulatory functions have been proposed to reduce the overwhelmed inflammation associated with COVID-19. Here we investigated the impact of IL-10 in COVID-19, through the ex-vivo assessment of the effects of exogenous IL-10 on SARS-CoV-2-specific-response using a whole-blood platform., Methods: Two cohorts were evaluated: in "study population A", plasma levels of 27 immune factors were measured by a multiplex (Luminex) assay in 39 hospitalized "COVID-19 patients" and 29 "NO COVID-19 controls" all unvaccinated. In "study population B", 29 COVID-19 patients and 30 NO COVID-19-Vaccinated Controls (NO COVID-19-VCs) were prospectively enrolled for the IL-10 study. Whole-blood was stimulated overnight with SARS-COV-2 antigens and then treated with IL-10. Plasma was collected and used for ELISA and multiplex assay. In parallel, whole-blood was stimulated and used for flow cytometry analysis., Results: Baseline levels of several immune factors, including IL-10, were significantly elevated in COVID-19 patients compared with NO COVID-19 subjects in "study population A". Among them, IL-2, FGF, IFN-γ, and MCP-1 reached their highest levels within the second week of infection and then decreased. To note that, MCP-1 levels remained significantly elevated compared with controls. IL-10, GM-CSF, and IL-6 increased later and showed an increasing trend over time. Moreover, exogenous addition of IL-10 significantly downregulated IFN-γ response and several other immune factors in both COVID-19 patients and NO COVID-19-VCs evaluated by ELISA and a multiplex analysis (Luminex) in "study population B". Importantly, IL-10 did not affect cell survival, but decreased the frequencies of T-cells producing IFN-γ, TNF-α, and IL-2 (p<0.05) and down-modulated HLA-DR expression on CD8
+ and NK cells., Conclusion: This study provides important insights into immune modulating effects of IL-10 in COVID-19 and may provide valuable information regarding the further in vivo investigations., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Najafi-Fard, Petruccioli, Farroni, Petrone, Vanini, Cuzzi, Salmi, Altera, Navarra, Alonzi, Nicastri, Palmieri, Gualano, Carlini, Noonan, Albini and Goletti.)- Published
- 2022
- Full Text
- View/download PDF
10. Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine.
- Author
-
Agrati C, Castilletti C, Goletti D, Sacchi A, Bordoni V, Mariotti D, Notari S, Matusali G, Meschi S, Petrone L, Aiello A, Najafi Fard S, Farroni C, Colavita F, Lapa D, Leone S, Agresta A, Capobianchi M, Ippolito G, Vaia F, and Puro V
- Subjects
- Antibodies, Neutralizing, Antibodies, Viral, BNT162 Vaccine, COVID-19 Vaccines, Humans, Immunity, Cellular, Immunity, Humoral, T-Lymphocytes, Vaccination, Vaccines, Synthetic, mRNA Vaccines, COVID-19 prevention & control, SARS-CoV-2
- Abstract
Vaccine is the main public health measure to reduce SARS-CoV-2 transmission and hospitalization, and a massive scientific effort worldwide resulted in the rapid development of effective vaccines. This work aimed to define the dynamics and persistence of humoral and cell-mediated immune response in Health Care Workers who received a two-dose BNT162b2-mRNA vaccination. Serological response was evaluated by quantifying anti-RBD and neutralizing antibodies while cell-mediated response was performed by a whole blood test quantifying Th1 cytokines (IFN-γ, TNF-α, IL-2) produced in response to Spike peptides. BNT162b2-mRNA vaccine induced both humoral and cell-mediated immune response against Spike in all HCW early after the second dose. After 12 weeks from vaccination, the titer of anti-RBD antibodies as well as their neutralization function decreased while the Spike-specific T-cells persisted at the same level as soon after vaccine boost. Of note, a correlation between cellular and humoral response persevered, suggesting the persistence of a coordinated immune response. The long lasting cell-mediated immune response after 3 months from vaccination highlight its importance in the maintaining of specific immunity able to expand again to fight eventual new antigen encountering., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
11. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
- Author
-
Alonzi T, Aiello A, Petrone L, Najafi Fard S, D'Eletto M, Falasca L, Nardacci R, Rossin F, Delogu G, Castilletti C, Capobianchi MR, Ippolito G, Piacentini M, and Goletti D
- Subjects
- Aged, Animals, COVID-19 virology, Cell Line, Tumor, Chlorocebus aethiops, Cystamine pharmacology, Cystine Depleting Agents pharmacology, Female, Humans, Male, Middle Aged, RNA, Viral genetics, RNA, Viral metabolism, SARS-CoV-2 genetics, SARS-CoV-2 physiology, Vero Cells, Virus Replication drug effects, Virus Replication genetics, Antiviral Agents pharmacology, Cysteamine pharmacology, Drug Repositioning methods, Immunomodulating Agents pharmacology, SARS-CoV-2 drug effects, COVID-19 Drug Treatment
- Abstract
The ongoing pandemic of coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), needs better treatment options both at antiviral and anti-inflammatory levels. It has been demonstrated that the aminothiol cysteamine, an already human applied drug, and its disulfide product of oxidation, cystamine, have anti-infective properties targeting viruses, bacteria, and parasites. To determine whether these compounds exert antiviral effects against SARS-CoV-2, we used different in vitro viral infected cell-based assays. Moreover, since cysteamine has also immune-modulatory activity, we investigated its ability to modulate SARS-CoV-2-specific immune response in vitro in blood samples from COVID-19 patients. We found that cysteamine and cystamine decreased SARS-CoV-2-induced cytopathic effects (CPE) in Vero E6 cells. Interestingly, the antiviral action was independent of the treatment time respect to SARS-CoV-2 infection. Moreover, cysteamine and cystamine significantly decreased viral production in Vero E6 and Calu-3 cells. Finally, cysteamine and cystamine have an anti-inflammatory effect, as they significantly decrease the SARS-CoV-2 specific IFN-γ production in vitro in blood samples from COVID-19 patients. Overall, our findings suggest that cysteamine and cystamine exert direct antiviral actions against SARS-CoV-2 and have in vitro immunomodulatory effects, thus providing a rational to test these compounds as a novel therapy for COVID-19.
- Published
- 2021
- Full Text
- View/download PDF
12. Multi-omics approach to COVID-19: a domain-based literature review.
- Author
-
Montaldo C, Messina F, Abbate I, Antonioli M, Bordoni V, Aiello A, Ciccosanti F, Colavita F, Farroni C, Najafi Fard S, Giombini E, Goletti D, Matusali G, Rozera G, Rueca M, Sacchi A, Piacentini M, Agrati C, Fimia GM, Capobianchi MR, Lauria FN, and Ippolito G
- Subjects
- Humans, Immunity, Innate, Pandemics, SARS-CoV-2, COVID-19
- Abstract
Background: Omics data, driven by rapid advances in laboratory techniques, have been generated very quickly during the COVID-19 pandemic. Our aim is to use omics data to highlight the involvement of specific pathways, as well as that of cell types and organs, in the pathophysiology of COVID-19, and to highlight their links with clinical phenotypes of SARS-CoV-2 infection., Methods: The analysis was based on the domain model, where for domain it is intended a conceptual repository, useful to summarize multiple biological pathways involved at different levels. The relevant domains considered in the analysis were: virus, pathways and phenotypes. An interdisciplinary expert working group was defined for each domain, to carry out an independent literature scoping review., Results: The analysis revealed that dysregulated pathways of innate immune responses, (i.e., complement activation, inflammatory responses, neutrophil activation and degranulation, platelet degranulation) can affect COVID-19 progression and outcomes. These results are consistent with several clinical studies., Conclusions: Multi-omics approach may help to further investigate unknown aspects of the disease. However, the disease mechanisms are too complex to be explained by a single molecular signature and it is necessary to consider an integrated approach to identify hallmarks of severity., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
13. ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients.
- Author
-
Picchianti-Diamanti A, Aiello A, Laganà B, Agrati C, Castilletti C, Meschi S, Farroni C, Lapa D, Najafi Fard S, Cuzzi G, Cimini E, Grassi G, Vanini V, Di Rosa R, Salemi S, Nalli G, Salmi A, Repele F, Altera AMG, Maffongelli G, Palazzolo C, Vita S, Leone S, Puro V, Capobianchi MR, Ippolito G, Nicastri E, and Goletti D
- Subjects
- Aged, Arthritis, Rheumatoid immunology, CD4-Positive T-Lymphocytes cytology, CD4-Positive T-Lymphocytes immunology, COVID-19 prevention & control, Female, Humans, Interferon-gamma immunology, Lymphocyte Count, Male, Middle Aged, SARS-CoV-2 immunology, Spike Glycoprotein, Coronavirus immunology, T-Lymphocytes cytology, Vaccines, Synthetic immunology, mRNA Vaccines, Antibodies, Viral immunology, Arthritis, Rheumatoid therapy, COVID-19 Vaccines immunology, Immunotherapy adverse effects, T-Lymphocytes immunology
- Abstract
Objective: To assess in rheumatoid arthritis (RA) patients, treated with different immunosuppressive therapies, the induction of SARS-CoV-2-specific immune response after vaccination in terms of anti-region-binding-domain (RBD)-antibody- and T-cell-specific responses against spike, and the vaccine safety in terms of clinical impact on disease activity., Methods: Health care workers (HCWs) and RA patients, having completed the BNT162b2-mRNA vaccination in the last 2 weeks, were enrolled. Serological response was evaluated by quantifying anti-RBD antibodies, while the cell-mediated response was evaluated by a whole-blood test quantifying the interferon (IFN)-γ-response to spike peptides. FACS analysis was performed to identify the cells responding to spike stimulation. RA disease activity was evaluated by clinical examination through the DAS28crp, and local and/or systemic clinical adverse events were registered. In RA patients, the ongoing therapeutic regimen was modified during the vaccination period according to the American College of Rheumatology indications., Results: We prospectively enrolled 167 HCWs and 35 RA patients. Anti-RBD-antibodies were detected in almost all patients (34/35, 97%), although the titer was significantly reduced in patients under CTLA-4-inhibitors (median: 465 BAU/mL, IQR: 103-1189, p<0.001) or IL-6-inhibitors (median: 492 BAU/mL, IQR: 161-1007, p<0.001) compared to HCWs (median: 2351 BAU/mL, IQR: 1389-3748). T-cell-specific response scored positive in most of RA patients [24/35, (69%)] with significantly lower IFN-γ levels in patients under biological therapy such as IL-6-inhibitors (median: 33.2 pg/mL, IQR: 6.1-73.9, p<0.001), CTLA-4-inhibitors (median: 10.9 pg/mL, IQR: 3.7-36.7, p<0.001), and TNF-α-inhibitors (median: 89.6 pg/mL, IQR: 17.8-224, p=0.002) compared to HCWs (median: 343 pg/mL, IQR: 188-756). A significant correlation between the anti-RBD-antibody titer and spike-IFN-γ-specific T-cell response was found in RA patients (rho=0.432, p=0.009). IFN-γ T-cell response was mediated by CD4
+ and CD8+ T cells. Finally, no significant increase in disease activity was found in RA patients following vaccination., Conclusion: This study showed for the first time that antibody-specific and whole-blood spike-specific T-cell responses induced by the COVID-19 mRNA-vaccine were present in the majority of RA patients, who underwent a strategy of temporary suspension of immunosuppressive treatment during vaccine administration. However, the magnitude of specific responses was dependent on the immunosuppressive therapy administered. In RA patients, BNT162b2 vaccine was safe and disease activity remained stable., Competing Interests: EN is a member of the advisory board by Gilead, Lilly and Roche and received fees for educational training by Gilead, Lilly and Roche. DG is member of the advisory board by Biomerieux and Eli-Lilly and received fees for educational training or consultancy by Biogen, Cellgene, Diasorin, Janssen, Qiagen, and Quidel. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Picchianti-Diamanti, Aiello, Laganà, Agrati, Castilletti, Meschi, Farroni, Lapa, Najafi Fard, Cuzzi, Cimini, Grassi, Vanini, Di Rosa, Salemi, Nalli, Salmi, Repele, Altera, Maffongelli, Palazzolo, Vita, Leone, Puro, Capobianchi, Ippolito, Nicastri and Goletti.)- Published
- 2021
- Full Text
- View/download PDF
14. Accuracy of an experimental whole-blood test for detecting reactivation of echinococcal cysts.
- Author
-
Petrone L, Tamarozzi F, Vola A, Gomez Morales MA, Ludovisi A, Najafi Fard S, Mariconti M, Brunetti E, and Goletti D
- Subjects
- Adult, Aged, Albendazole therapeutic use, Animals, Cytokines blood, Echinococcosis drug therapy, Female, Hematologic Tests, Humans, Life Cycle Stages immunology, Male, Middle Aged, Prospective Studies, Treatment Outcome, Cysts immunology, Echinococcosis blood, Echinococcus granulosus immunology, Interleukin-4 blood
- Abstract
Background: Cystic echinococcosis (CE) is a complex disease for which clear understanding of clinical manifestations is needed to avoid misdiagnosis, inappropriate treatment, and severe complications. We evaluated the accuracy of a whole-blood stimulation test based on Interleukin (IL)-4 detection in response to Antigen B (AgB) of Echinococcus granulosus sensu lato to discriminate cyst viability and detect cyst reactivation in patients with hepatic CE., Methodology/principal Findings: Thirty patients with CE3b cysts and 37 patients with spontaneously-inactivated CE4-CE5 cysts were recruited (T0). After enrollment, 5 patients with CE3b cysts received albendazole, resulting in cyst solidification (CE4) in 4/5. Within a two-year follow-up, the whole-blood test was repeated at two time-points, in ≥14 (T1) and in ≥4 (T2) patients per group. IL-4 and a panel of other soluble factors were measured in the stimulated plasma. Baseline IL-4 levels were significantly higher in patients with CE3b compared to those with CE4 cysts (p = 0.006). Test accuracy for CE3b diagnosis had a sensitivity of 33-60% and a specificity of 76-95%, depending on the cut-off applied. Overall, IL-4 levels did not change significantly over time in either group; however, patients within the CE3b group showed a significant decrease of IL-1ra, IL-6, IL-8, G-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, FGF at T1 compared to T0 (p≤0.042)., Conclusions/significance: Whole-blood IL-4-response to AgB is significantly higher in patients with active compared to inactive CE but apparently not modulated over time after treatment. On the contrary, the levels of IL-1ra, IL-6, IL-8, G-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, FGF significantly decreased in active CE during follow-up. Additional studies are needed to understand whether these findings might have a clinical significance for patients' follow-up., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2021
- Full Text
- View/download PDF
15. Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection.
- Author
-
Petruccioli E, Najafi Fard S, Navarra A, Petrone L, Vanini V, Cuzzi G, Gualano G, Pierelli L, Bertoletti A, Nicastri E, Palmieri F, Ippolito G, and Goletti D
- Subjects
- Biomarkers, COVID-19 Vaccines, Humans, RNA, Viral, SARS-CoV-2, COVID-19
- Abstract
Background: Recent studies proposed the whole-blood based IFN-γ-release assay to study the antigen-specific SARS-CoV-2 response. Since the early prediction of disease progression could help to assess the optimal treatment strategies, an integrated knowledge of T-cell and antibody response lays the foundation to develop biomarkers monitoring the COVID-19. Whole-blood-platform tests based on the immune response detection to SARS-CoV2 peptides is a new approach to discriminate COVID-19-patients from uninfected-individuals and to evaluate the immunogenicity of vaccine candidates, monitoring the immune response in vaccine trial and supporting the serological diagnostics results. Here, we aimed to identify in the whole-blood-platform the best immunogenic viral antigen and the best immune biomarker to identify COVID-19-patients., Methods: Whole-blood was overnight-stimulated with SARS-CoV-2 peptide pools of nucleoprotein-(NP) Membrane-, ORF3a- and Spike-protein. We evaluated: IL-1β, IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL- 15, IL-17A, eotaxin, FGF, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF, RANTES, TNF-α, VEGF. By a sparse partial least squares discriminant analysis we identified the most important soluble factors discriminating COVID-19- from NO-COVID-19-individuals., Results: We identified a COVID-19 signature based on six immune factors: IFN-γ, IP-10 and IL-2 induced by Spike; RANTES and IP-10 induced by NP and IL-2 induced by ORF3a. We demonstrated that the test based on IP-10 induced by Spike had the highest AUC (0.85, p < 0.0001) and that the clinical characteristics of the COVID-19-patients did not affect IP-10 production. Finally, we validated the use of IP-10 as biomarker for SARS-CoV2 infection in two additional COVID-19-patients cohorts., Conclusions: We set-up a whole-blood assay identifying the best antigen to induce a T-cell response and the best biomarkers for SARS-CoV-2 infection evaluating patients with acute COVID-19 and recovered patients. We focused on IP-10, already described as a potential biomarker for other infectious disease such as tuberculosis and HCV. An additional application of this test is the evaluation of immune response in SARS-CoV-2 vaccine trials: the IP-10 detection may define the immunogenicity of a Spike-based vaccine, whereas the immune response to the virus may be evaluated detecting other soluble factors induced by other viral-antigens.
- Published
- 2021
- Full Text
- View/download PDF
16. In Vitro Models for Studying Entry, Tissue Tropism, and Therapeutic Approaches of Highly Pathogenic Coronaviruses.
- Author
-
Najafi Fard S, Petrone L, Petruccioli E, Alonzi T, Matusali G, Colavita F, Castilletti C, Capobianchi MR, and Goletti D
- Subjects
- COVID-19, Cells, Cultured, Coronaviridae Infections, Humans, SARS-CoV-2, Spike Glycoprotein, Coronavirus chemistry, Spike Glycoprotein, Coronavirus metabolism, Antiviral Agents chemistry, Antiviral Agents pharmacology, Coronaviridae drug effects, Coronaviridae metabolism, Coronaviridae pathogenicity, Coronaviridae physiology, Models, Biological, Viral Tropism, Virus Internalization
- Abstract
Coronaviruses (CoVs) are enveloped nonsegmented positive-sense RNA viruses belonging to the family Coronaviridae that contain the largest genome among RNA viruses. Their genome encodes 4 major structural proteins, and among them, the Spike (S) protein plays a crucial role in determining the viral tropism. It mediates viral attachment to the host cell, fusion to the membranes, and cell entry using cellular proteases as activators. Several in vitro models have been developed to study the CoVs entry, pathogenesis, and possible therapeutic approaches. This article is aimed at summarizing the current knowledge about the use of relevant methodologies and cell lines permissive for CoV life cycle studies. The synthesis of this information can be useful for setting up specific experimental procedures. We also discuss different strategies for inhibiting the binding of the S protein to the cell receptors and the fusion process which may offer opportunities for therapeutic intervention., Competing Interests: The authors declare that there is no conflict of interest regarding the publication of this article., (Copyright © 2021 Saeid Najafi Fard et al.)
- Published
- 2021
- Full Text
- View/download PDF
17. Impact of Prior Influenza and Pneumoccocal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination.
- Author
-
Puro V, Castilletti C, Agrati C, Goletti D, Leone S, Agresta A, Cimini E, Tartaglia E, Casetti R, Colavita F, Meschi S, Matusali G, Lapa D, Najafi Fard S, Aiello A, Farrone C, Gallì P, Capobianchi MR, Ippolito G, and On Behalf Of The Inmi Covid-Vaccine Study Group
- Abstract
Vaccination against SARS-CoV-2 is considered the most effective method of prevention to contain the pandemic. While highly effective SARS-CoV-2 vaccines are being applied on a large-scale, whether and to what extent the strength of the vaccine-induced immune response could be further potentiated is still an object of debate. Several reports studied the effect of different vaccines on the susceptibility and mortality of COVID-19, with conflicting results. We aimed to evaluate whether previous influenza and/or pneumococcal vaccination had an impact on the specific immune response to the SARS-CoV-2 BNT162b2 mRNA vaccine. The study population consists of 710 workers from our Institute who completed the BNT162b2 schedule and have been tested at least once after the second dose, from 27 December 2020 up to 15 April 2021. Of these, 152 (21.4%) had received an influenza and 215 (30.3%) a concomitant influenza and pneumococcal vaccination, a median of 102 days before the second dose of BNT162b2. Overall, 100% of workers were tested for anti-Spike receptor-binding domain (anti-S/RBD) antibodies, 224 workers for neutralization titer (Micro-neutralization assay, MNA), and 155 workers for a spike-specific T cell interferon-γ response (IFN-γ). The levels of anti-S/RBD, MNA and IFN-γ were evaluated and compared according to sex, age, involvement in direct care of COVID-19 patients, and previous influenza/pneumococcal vaccination. At the univariate analysis, no statistically significant association was observed with regard to a previous influenza and pneumococcal vaccination. A significant lower anti-S/RBD response was observed according to an older age and male sex, while MNA titers were significantly associated to sex but not to age. At the multivariable analysis, workers receiving a concomitant influenza and pneumococcal vaccination or only influenza showed a 58% ( p 0.01) and 42% ( p 0.07) increase in MNA titers, respectively, compared to those who did not receive an influenza/pneumococcal vaccination. Female workers showed an 81% MNA and a 44% anti-S/RBD increase compared to male workers ( p < 0.001). Compared to workers aged 21 to 49 years, those aged 50 or older were associated with a reduction in the anti-S/RBD (16%; p 0.005), MNA (31%; p 0.019), and IFN.g (32%) immune response. Maintaining the influenza and pneumococcal immunization program for the coming season, in which COVID-19 could still be spreading, remains strongly recommended to protect those who are more vulnerable and to limit the potential burden of these infections on the healthcare system.
- Published
- 2021
- Full Text
- View/download PDF
18. Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients.
- Author
-
Aiello A, Najafi Fard S, Petruccioli E, Petrone L, Vanini V, Farroni C, Cuzzi G, Navarra A, Gualano G, Mosti S, Pierelli L, Nicastri E, and Goletti D
- Subjects
- Acute Disease, Adult, Antibodies, Viral blood, CD8-Positive T-Lymphocytes immunology, Humans, Middle Aged, Antigens, Viral immunology, COVID-19 blood, COVID-19 immunology, Spike Glycoprotein, Coronavirus immunology
- Abstract
Objectives: To identify the best experimental approach to detect a SARS-CoV-2-specific T cell response using a whole-blood platform., Methods: Whole-blood from 56 COVID-19 and 23 "NO-COVID-19" individuals were stimulated overnight with different concentrations (0.1 or 1 μg/mL) of SARS-CoV-2 PepTivator® Peptide Pools, including spike (pool S), nucleocapsid (pool N), membrane (pool M), and a MegaPool (MP) of these three peptide pools. ELISA was used to analyse interferon (IFN)-γ levels., Results: The IFN-γ-response to every SARS-CoV-2 peptide pool was significantly increased in COVID-19 patients compared with NO-COVID-19 individuals. Pool S and MegaPool were the most potent immunogenic stimuli (median: 0.51, IQR: 0.14-2.17; and median: 1.18, IQR: 0.27-4.72, respectively) compared with pools N and M (median: 0.22, IQR: 0.032-1.26; and median: 0.22, IQR: 0.01-0.71, respectively). The whole-blood test based on pool S and MegaPool showed a good sensitivity of 77% and a high specificity of 96%. The IFN-γ-response was mediated by both CD4
+ and CD8+ T cells, and independently detected of clinical parameters in both hospitalized and recovered patients., Conclusions: This easy-to-use assay for detecting SARS-CoV-2-specific T cell responses may be implemented in clinical laboratories as a powerful diagnostic tool., (Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
19. In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy.
- Author
-
Petrone L, Petruccioli E, Alonzi T, Vanini V, Cuzzi G, Najafi Fard S, Castilletti C, Palmieri F, Gualano G, Vittozzi P, Nicastri E, Lepore L, Grifoni A, Antinori A, Vergori A, Ippolito G, Cantini F, and Goletti D
- Subjects
- Azetidines, Cytokines, Humans, Purines, Pyrazoles, SARS-CoV-2, Sulfonamides, COVID-19 Drug Treatment
- Abstract
Objective: Baricitinib seems a promising therapy for COVID-19. To fully-investigate its effects, we in-vitro evaluated the impact of baricitinib on the SARS-CoV-2-specific-response using the whole-blood platform., Methods: We evaluated baricitinib effect on the IFN-γ-release and on a panel of soluble factors by multiplex-technology after stimulating whole-blood from 39 COVID-19 patients with SARS-CoV-2 antigens. Staphylococcal Enterotoxin B (SEB) antigen was used as a positive control., Results: In-vitro exogenous addition of baricitinib significantly decreased IFN-γ response to spike- (median: 0.21, IQR: 0.01-1; spike+baricitinib 1000 nM median: 0.05, IQR: 0-0.18; p < 0.0001) and to the remainder-antigens (median: 0.08 IQR: 0-0.55; remainder-antigens+baricitinib 1000 nM median: 0.03, IQR: 0-0.14; p = 0.0013). Moreover, baricitinib significantly decreased SEB-induced response (median: 12.52, IQR: 9.7-15.2; SEB+baricitinib 1000 nM median: 8, IQR: 1.44-12.16; p < 0.0001). Baricitinib did modulate other soluble factors besides IFN-γ, significantly decreasing the spike-specific-response mediated by IL-17, IL-1β, IL-6, TNF-α, IL-4, IL-13, IL-1ra, IL-10, GM-CSF, FGF, IP-10, MCP-1, MIP-1β (p ≤ 0.0156). The baricitinib-decreased SARS-CoV-2-specific-response was observed mainly in mild/moderate COVID-19 and in those with lymphocyte count ≥1 × 10
3 /µl., Conclusions: Exogenous addition of baricitinib decreases the in-vitro SARS-CoV-2-specific response in COVID-19 patients using a whole-blood platform. These results are the first to show the effects of this therapy on the immune-specific viral response., Competing Interests: Declaration of Competing Interest Dr Emanuele Nicastri reported consultancies from Gilead under $10,000 and outside the present work. Dr Alba Grifoni is listed as inventor on a provisional patent application on the diagnostic and therapeutic use of the MPs and peptides thereof filed on February 12, 2020. Dr Andrea Antinori reported consultancies, speaking fees and honoraria from Gilead Sciences, Janssen Cilag, Merk, VIIVHealthcare, Theratechnologies, all under $10,000 and outside the present work. Dr Alessandra Vergori received institutional grants from Gilead, travel grants and speaker's fees from Janssen and speaker's fee from MSD, all under $10,000 and outside the present work. Dr Delia Goletti reported consultancies from Quidel and Biomeriuex and speaking fees from Diasorin and Janssen, all under $10,000 and outside the present work.All the other authors have declared that no conflict of interest and/or financial disclosures exists., (Copyright © 2021. Published by Elsevier Ltd.)- Published
- 2021
- Full Text
- View/download PDF
20. A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients.
- Author
-
Petrone L, Petruccioli E, Vanini V, Cuzzi G, Najafi Fard S, Alonzi T, Castilletti C, Palmieri F, Gualano G, Vittozzi P, Nicastri E, Lepore L, Antinori A, Vergori A, Caccamo N, Cantini F, Girardi E, Ippolito G, Grifoni A, and Goletti D
- Subjects
- Adult, Aged, Antigens, Viral immunology, COVID-19 blood, Cytokines blood, Cytokines immunology, Female, Humans, Immunoglobulin G blood, Immunoglobulin G immunology, Interferon-gamma blood, Interferon-gamma immunology, Male, Middle Aged, Spike Glycoprotein, Coronavirus immunology, Th1 Cells immunology, Th2 Cells immunology, COVID-19 immunology, COVID-19 Serological Testing methods, SARS-CoV-2 immunology
- Abstract
Objectives: To examine whether specific T-cell-responses to SARS-CoV-2 peptides can be detected in COVID-19 using a whole-blood experimental setting, which may be further explored as a potential diagnostic tool., Methods: We evaluated interferon (IFN)-γ levels after stimulating whole-blood with spike and remainder-antigens peptides megapools (MP) derived from SARS-CoV-2 sequences; interleukin (IL)-1β, IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17A, eotaxin, basic fibroblast growth factor (FGF), granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), IFN-γ, Interferon gamma-induced protein 10 (IP-10), monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein (MIP)-1α, MIP-1β, Platelet-derived growth factor (PDGF), RANTES (regulated on activation, normal T cell expressed and secreted), tumour necrosis factor-alpha (TNF-α), vascular endothelial growth factor (VEGF) were also evaluated., Results: IFN-γ-response to spike and remainder-antigens MPs was significantly increased in 35 COVID-19 patients compared with 29 'no COVID-19' individuals (medians spike-MP: 0.26 vs 0, p = 0.0002; medians remainder-antigens-MP: 0.07 vs 0.02; p = 0.02). This response was detected independently of patients' clinical parameters. IFN-γ-response to SARS-CoV-2-unrelated antigens cytomegalovirus (CMV) and Staphylococcal Enterotoxin B (SEB) was similar in COVID-19 compared with 'no COVID-19' individuals (median CMV: 3.46 vs 5.28, p = 0.16; median SEB: 12.68 vs 15.05; p = 0.1). In response to spike-MPs in COVID-19- compared with 'no COVID-19' -individuals, we found significant higher median of IL-2 (50.08 vs 0, p = 0.0018), IFN-γ (90.16 vs 0, p = 0.01), IL-4 (0.52 vs 0, p = 0.03), IL-13 (0.84 vs 0, p = 0.007) and MCP-1 (4602 vs 359.2, p = 0.05)., Conclusions: Immune response to SARS-CoV-2 peptides in a whole-blood assay is associated with COVID-19 and it is characterized by both Th1 and Th2 profile. This experimental approach may be useful for developing new T-cell based diagnostic tests for disease and vaccine settings., (Copyright © 2020. Published by Elsevier Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
21. Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review.
- Author
-
Cantini F, Goletti D, Petrone L, Najafi Fard S, Niccoli L, and Foti R
- Subjects
- Adenosine Monophosphate analogs & derivatives, Adenosine Monophosphate therapeutic use, Alanine analogs & derivatives, Alanine therapeutic use, Anti-Inflammatory Agents administration & dosage, Antibodies, Monoclonal, Humanized, Antiviral Agents administration & dosage, Biological Products administration & dosage, COVID-19 therapy, Cytokines drug effects, Cytokines metabolism, Dexamethasone therapeutic use, Drug Therapy, Combination, Humans, Inflammation Mediators metabolism, Intensive Care Units, Pandemics, Retrospective Studies, SARS-CoV-2, Anti-Inflammatory Agents therapeutic use, Antiviral Agents therapeutic use, Biological Products therapeutic use, COVID-19 Drug Treatment
- Abstract
Background: Based on current evidence, recent guidelines of the National Institute of Health, USA indicated the use of remdesivir and dexamethasone for the treatment of COVID-19 patients with mild-moderate disease, not requiring high-flow oxygen. No therapeutic agent directed against the immunologic pathogenic mechanisms related to the cytokine release syndrome complicating the disease was indicated., Objectives: The purpose of this review was to assess the clinical impact of different therapies for COVID-19; thus, helping to identify the optimal management of the disease. To explain the rationale for the different therapeutic approaches, the characteristics of SARS-CoV-2, the pathogenesis of COVID-19, and the immune response triggered by SARS-CoV-2 infection were reported., Methods: The efficacy assessment of the different treatments was performed by a systematic review in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Available English language published articles including randomised controlled trials, open-label trials of antivirals and immune therapies extracted from Medline, Google Scholar, and MedRxiv databases were analysed. For inclusion, the primary end point of the trials had to be the efficacy as measured by the improvement of clinical features, or mortality, or the Intensive Care Unit Admission rate, or the discharge number. Case reports, paediatric studies, and studies without control group were excluded. The literature search was extended up to August 15, 2020., Results: After the removal of duplicate articles, and the exclusion of studies not meeting the eligibility criteria, 2 trials of lopinavir/ritonavir, 1 of favipiravir, 3 of remdesivir, 1 of dexamethasone, 3 of hydroxychloroquine, 2 of colchicine, 6 of tocilizumab, 1 of sarilumab, 1 of siltuximab, 2 of anakinra, 3 of baricitinib, 1 of ruxolitinib, 1 of mavrilimumab, and 1 of itolizumab were suitable for the review. Among antivirals, only remdesivir significantly reduced the time to recovery, and mortality. Data for chloroquine and hydroxychloroquine were largely inconclusive. In a large trial, dexamethasone 6 mg/day reduced mortality by one-third. Trials of tocilizumab and sarilumab did not definitively demonstrate efficacy. Anakinra significantly reduced the mortality in 2 trials. Three retrospective trials on a cumulative number of 145 patients, reported the efficacy of baricitinib, with significant reduction of intensive care unit admission, and deaths. These results were recently confirmed by the ACTT-2 trial. Due to paucity of studies and to the small size clinical series, the results of other immune therapies were not conclusive., Conclusions: Beyond the supportive therapy, up to now the best therapeutic approach for COVID-19 may be a three-step combination therapy, including remdesivir 100 mg/day (200 mg loading dose on first day) in the first stage of the disease, and combined dexamethasone 6 mg/day plus baricitinib 4 mg/day to target the immune dysregulation triggered by the SARS-CoV-2 infection. The promising results of anakinra should be confirmed by the ongoing RCTs.
- Published
- 2020
- Full Text
- View/download PDF
22. Epidemic and pandemic viral infections: impact on tuberculosis and the lung: A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycobacterial Infections (ESGMYC).
- Author
-
Ong CWM, Migliori GB, Raviglione M, MacGregor-Skinner G, Sotgiu G, Alffenaar JW, Tiberi S, Adlhoch C, Alonzi T, Archuleta S, Brusin S, Cambau E, Capobianchi MR, Castilletti C, Centis R, Cirillo DM, D'Ambrosio L, Delogu G, Esposito SMR, Figueroa J, Friedland JS, Ho BCH, Ippolito G, Jankovic M, Kim HY, Rosales Klintz S, Ködmön C, Lalle E, Leo YS, Leung CC, Märtson AG, Melazzini MG, Najafi Fard S, Penttinen P, Petrone L, Petruccioli E, Pontali E, Saderi L, Santin M, Spanevello A, van Crevel R, van der Werf MJ, Visca D, Viveiros M, Zellweger JP, Zumla A, and Goletti D
- Subjects
- BCG Vaccine therapeutic use, Betacoronavirus, COVID-19, Coronavirus Infections diagnosis, Coronavirus Infections drug therapy, Coronavirus Infections epidemiology, Coronavirus Infections immunology, Epidemics, HIV Infections diagnosis, HIV Infections drug therapy, HIV Infections epidemiology, HIV Infections immunology, Humans, Influenza A Virus, H1N1 Subtype, Influenza, Human diagnosis, Influenza, Human drug therapy, Influenza, Human epidemiology, Influenza, Human immunology, Lung immunology, Middle East Respiratory Syndrome Coronavirus, Pandemics, Pneumonia, Viral diagnosis, Pneumonia, Viral drug therapy, Pneumonia, Viral epidemiology, Pneumonia, Viral immunology, Public Health, Respiratory Tract Infections diagnosis, Respiratory Tract Infections drug therapy, Respiratory Tract Infections immunology, SARS-CoV-2, Severe Acute Respiratory Syndrome diagnosis, Severe Acute Respiratory Syndrome drug therapy, Severe Acute Respiratory Syndrome epidemiology, Severe Acute Respiratory Syndrome immunology, Tuberculosis diagnosis, Tuberculosis immunology, Tuberculosis prevention & control, Virus Diseases diagnosis, Virus Diseases drug therapy, Virus Diseases immunology, Respiratory Tract Infections epidemiology, Tuberculosis epidemiology, Virus Diseases epidemiology
- Abstract
Major epidemics, including some that qualify as pandemics, such as severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), HIV, influenza A (H1N1)pdm/09 and most recently COVID-19, affect the lung. Tuberculosis (TB) remains the top infectious disease killer, but apart from syndemic TB/HIV little is known regarding the interaction of viral epidemics and pandemics with TB. The aim of this consensus-based document is to describe the effects of viral infections resulting in epidemics and pandemics that affect the lung (MERS, SARS, HIV, influenza A (H1N1)pdm/09 and COVID-19) and their interactions with TB. A search of the scientific literature was performed. A writing committee of international experts including the European Centre for Disease Prevention and Control Public Health Emergency (ECDC PHE) team, the World Association for Infectious Diseases and Immunological Disorders (WAidid), the Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Mycobacterial Infections (ESGMYC) was established. Consensus was achieved after multiple rounds of revisions between the writing committee and a larger expert group. A Delphi process involving the core group of authors (excluding the ECDC PHE team) identified the areas requiring review/consensus, followed by a second round to refine the definitive consensus elements. The epidemiology and immunology of these viral infections and their interactions with TB are discussed with implications for diagnosis, treatment and prevention of airborne infections (infection control, viral containment and workplace safety). This consensus document represents a rapid and comprehensive summary on what is known on the topic., Competing Interests: Conflict of interest: G.B. Migliori has nothing to disclose. Conflict of interest: M. Raviglione has nothing to disclose. Conflict of interest: G. MacGregor-Skinner has nothing to disclose. Conflict of interest: G. Sotgiu has nothing to disclose. Conflict of interest: J-W. Alffenaar has nothing to disclose. Conflict of interest: S. Tiberi has nothing to disclose. Conflict of interest: C. Adlhoch has nothing to disclose. Conflict of interest: T. Alonzi has nothing to disclose. Conflict of interest: S. Archuleta has nothing to disclose. Conflict of interest: S. Brusin has nothing to disclose. Conflict of interest: E. Cambau has nothing to disclose. Conflict of interest: M.R. Capobianchi has nothing to disclose. Conflict of interest: C. Castilletti has nothing to disclose. Conflict of interest: R. Centis has nothing to disclose. Conflict of interest: D.M. Cirillo has nothing to disclose. Conflict of interest: L. D'Ambrosio has nothing to disclose. Conflict of interest: G. Delogu has nothing to disclose. Conflict of interest: S.M.R. Esposito has nothing to disclose. Conflict of interest: J. Figueroa has nothing to disclose. Conflict of interest: J.S. Friedland has nothing to disclose. Conflict of interest: B.C.H. Ho has nothing to disclose. Conflict of interest: G. Ippolito has nothing to disclose. Conflict of interest: M. Jankovic has nothing to disclose. Conflict of interest: H.Y. Kim has nothing to disclose. Conflict of interest: S. Rosales Klintz has nothing to disclose. Conflict of interest: C. Ködmön has nothing to disclose. Conflict of interest: E. Lalle has nothing to disclose. Conflict of interest: Y.S. Leo has nothing to disclose. Conflict of interest: C-C. Leung has nothing to disclose. Conflict of interest: A-G. Märtson has nothing to disclose. Conflict of interest: M.G. Melazzini has nothing to disclose. Conflict of interest: S. Najafi Fard has nothing to disclose. Conflict of interest: P. Penttinen has nothing to disclose. Conflict of interest: L. Petrone has nothing to disclose. Conflict of interest: E. Petruccioli has nothing to disclose. Conflict of interest: E. Pontali has nothing to disclose. Conflict of interest: L. Saderi has nothing to disclose. Conflict of interest: M. Santin has nothing to disclose. Conflict of interest: A. Spanevello has nothing to disclose. Conflict of interest: R. van Crevel has nothing to disclose. Conflict of interest: M.J. van der Werf has nothing to disclose. Conflict of interest: D. Visca has nothing to disclose. Conflict of interest: M. Viveiros has nothing to disclose. Conflict of interest: J-P. Zellweger has nothing to disclose. Conflict of interest: A. Zumla has nothing to disclose. Conflict of interest: D. Goletti has nothing to disclose. Conflict of interest: C.W.M. Ong has nothing to disclose., (Copyright ©ERS 2020.)
- Published
- 2020
- Full Text
- View/download PDF
23. Direct-acting antiviral therapy enhances total CD4+ and CD8+ T-cells responses, but does not alter T-cells activation among HCV mono-infected, and HCV/HIV-1 co-infected patients.
- Author
-
Najafi Fard S, Schietroma I, Corano Scheri G, Giustini N, Serafino S, Cavallari EN, Pinacchio C, De Girolamo G, Ceccarelli G, Scagnolari C, Vullo V, and d'Ettorre G
- Subjects
- Adult, Case-Control Studies, Coinfection, Cytokines blood, Female, Flow Cytometry, HIV Infections immunology, Hepatitis C, Chronic immunology, Humans, Lymphocyte Activation, Male, Middle Aged, Antiviral Agents therapeutic use, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes immunology, HIV Infections drug therapy, Hepatitis C, Chronic drug therapy
- Abstract
Aim: Chronic immune activation and poor T-cell immune response are strongly associated with disease progression and pathogenesis of both hepatitis C virus (HCV) and human immunodeficiency virus (HIV)-1 infections. Little is known about the impact of anti-HCV Interferon (IFN)-free direct-acting antiviral (DAA) therapy on the systemic T-cells activation and patterns of peripheral T-cells producing pro-inflammatory cytokines., Patients and Methods: Forty-five subjects including 18 HCV mono-infected, 17 HCV/HIV-1 co-infected patients under antiretroviral therapy (ART), and 10 healthy controls (HCs) were recruited. Blood samples were collected at baseline (T0) and 12 weeks after the end of DAA therapy (T1). Cell phenotypes (CD3, CD4, CD8), activation markers (CD38 and HLA-DR), and frequency of IFN-γ, interleukin (IL)-17, and IL-22 producing CD4+ and CD8+ T-cells were measured by flow cytometry. Plasma levels of related cytokines were also measured by enzyme-linked immunosorbent assay (ELISA)., Results: Both HCV, and HCV/HIV-1 patients before and after therapy, showed significant higher percentages of any T-cell subset expressing CD38 and/or HLA-DR compared to HCs. No differences were observed in T-cells activation at T1 compared to T0 in patient groups, and when HCV patients were compared to HCV/HIV-1 group (P>0.05). After therapy, the potential of total circulating T helper (Th) and T cytotoxic (Tc) cells producing IFN-γ, IL-17, and IL-22 were increased. Plasma level of IFN-γ at baseline was showed difference compared to HCs, and significantly reduced after therapy (P<0.05)., Conclusion: Total T-cells immune response enhances after therapy, however, the state of immune activation may remain elevated for a longtime after the end of treatment and contribute to post-Sustained Virologic Response (SVR) consequences., (Copyright © 2017 Elsevier Masson SAS. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
24. Probiotics Differently Affect Gut-Associated Lymphoid Tissue Indolamine-2,3-Dioxygenase mRNA and Cerebrospinal Fluid Neopterin Levels in Antiretroviral-Treated HIV-1 Infected Patients: A Pilot Study.
- Author
-
Scagnolari C, Corano Scheri G, Selvaggi C, Schietroma I, Najafi Fard S, Mastrangelo A, Giustini N, Serafino S, Pinacchio C, Pavone P, Fanello G, Ceccarelli G, Vullo V, and d'Ettorre G
- Abstract
Recently the tryptophan pathway has been considered an important determinant of HIV-1 infected patients' quality of life, due to the toxic effects of its metabolites on the central nervous system (CNS). Since the dysbiosis described in HIV-1 patients might be responsible for the microbial translocation, the chronic immune activation, and the altered utilization of tryptophan observed in these individuals, we speculated a correlation between high levels of immune activation markers in the cerebrospinal fluid (CSF) of HIV-1 infected patients and the over-expression of indolamine-2,3-dioxygenase (IDO) at the gut mucosal surface. In order to evaluate this issue, we measured the levels of neopterin in CSF, and the expression of IDO mRNA in gut-associated lymphoid tissue (GALT), in HIV-1-infected patients on effective combined antiretroviral therapy (cART), at baseline and after six months of probiotic dietary management. We found a significant reduction of neopterin and IDO mRNA levels after the supplementation with probiotic. Since the results for the use of adjunctive therapies to reduce the levels of immune activation markers in CSF have been disappointing so far, our pilot study showing the efficacy of this specific probiotic product should be followed by a larger confirmatory trial., Competing Interests: The authors declare no conflict of interest.
- Published
- 2016
- Full Text
- View/download PDF
25. Influenza A virus among the hospitalized young children with acute respiratory infection. Is influenza A co infected with respiratory syncytial virus?
- Author
-
Alavi SM, Makvandi M, Najafi-Fard S, and Alavi L
- Abstract
Background: Both influenza A virus (IAV) and respiratory syncytial virus (RSV) cause acute respiratory infection (ARI) in infants and young children. This study was conducted to determine Influenza A virus and its co infection with RSV among the hospitalized children with ARI., Methods: A total of 153 throat samples of the hospitalized young children aged between below one year and 5 years with the clinical signs of ARI were collected from the different hospitals in Khuzestan from June 2009 to April 2010. The samples were tested for Influenza A viruses by real time PCR. Positive IAV samples were tested for influenza A sub type H1N1 and for RSV by the nested PCR., Results: In this study, from the total 153 samples, 35 samples (22.9%) including 15 (42.8%) females and 20 (57.2%) males were positive for influenza A viruses. From the 35 positive samples for IAV, 14 were positive for swine H1N1 subtype. All the positive samples for influenza showed negative for RSV infection which revealed no coinfection with RSV. The prevalence of influenza A among age/sex groups was not significant., Conclusion: Influenza A is a prevalent viral agent isolated from young children with ARI. Influenza A subtype H1N1 was accounted for the 40 percent all laboratory-proven diagnoses of influenza in 2009. No evidence of coinfection of influenza A and RSV has been observed in the present study.
- Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.